CARTHERICS RAISES OVER $15 MILLION IN OVERSUBSCRIBED PRIVATE FINANCING ROUND TO ADVANCE CELL THERAPY PROGRAMS

• Financing round was significantly oversubscribed by existing investors and new private investors. 

• Funding will enable the Company to progress clinical trials of its lead CAR-NK cell therapy product, CTH-401, in ovarian cancer and expand its pipeline to additional disease indications.

Melbourne, Australia, 1 October 2024 –  Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer and other diseases, is pleased to announce that it has successfully raised well over its target AU$15M in an oversubscribed financing round. 

This funding will support the initiation of the clinical trial for CTH-401, the Company’s lead cell therapy product, aimed at treating ovarian cancer, as well as broadening its pipeline to include other disease indications.

Cartherics’ Chief Executive Officer, Prof. Alan Trounson AO commented: “The successful capital raising, in times of scant investment support in biotechnology, is welcome and further supports confidence in the company for the delivery of effective therapies in ovarian cancer and other difficult diseases.” 

Despite advancements in surgical and chemotherapy treatments for ovarian cancer, survival rates remain very low.  This is largely due to late diagnosis and the lack of  options for patients who are refractory to approved therapies, highlighting the need for new treatment options for these patients. 

CTH-401 is the only natural killer (NK) cell product currently under development that incorporates a chimeric antigen receptor (CAR) that targets the adenocarcinoma specific antigen, TAG-72. TAG-72 is a well-validated tumour marker that is widely expressed in a range of solid tumours, including ovarian, gastric, colorectal, prostate and pancreatic cancers. 

Cartherics has demonstrated that CTH-401 is very effective in killing ovarian cancer cells in both tissue culture and animal models, with initiation of the first clinical trial planned for next year.

Cartherics’ Chairman, Bob Moses said: “We are eager to initiate the clinical trial for CTH-401, building on the promising results from our preclinical studies. This important milestone underscores our commitment to delivering innovative treatments for ovarian cancer and highlights the confidence our investors have in our vision to enhance patient outcomes and drive growth.”

The global market for ovarian cancer drugs is estimated at US$3.5 billion in 2023 and is projected to reach US$4.8 billion by 2030.[i] The natural killer cell therapeutics market was valued at US$350.5 million in 2024 and is projected to grow at a CAGR of 41.70% to reach US$11.4 billion by 2034.[ii]

****** 

About Cartherics   

Cartherics Pty Ltd is a privately held biotechnology company based in Melbourne, Australia that is rearming the body’s immune system to fight cancer.  It is developing cell-based immunotherapies for the treatment of cancer, with a portfolio of CAR-T and CAR-NK cell products.  The Company’s allogeneic (“off-the-shelf”) cell platform is based upon induced pluripotent stem cells (iPSCs) generated from donated cord blood that can be differentiated into NK cells, T cells and other cells of the immune system.  The iPSCs are genetically engineered at specific “safe harbour” genomic sites to provide enhanced function for the derived NK and other immune cells.  The Company’s lead product, CTH-401, is a CAR-NK cell product.  It carries a CAR directed against TAG-72, a well-validated tumour target, along with the deletion of two genes associated with immunosuppression.   

https://cartherics.com/  

Christine Filippis   

Teraze Communications  

Phone: +61 419 119 866   

Email: [email protected]